New drug combo tested for Tough-to-Treat skin cancer
NCT ID NCT06984328
Summary
This study is testing a new drug called acasunlimab, given alone or together with the cancer drug pembrolizumab, for people with advanced skin melanoma that has continued to grow despite prior immunotherapy. The main goal is to see if the treatment can shrink tumors and is safe. All participants will receive active treatment; no one will get a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pan American Center for Oncology Trials, LLC
San Juan, 00909, Puerto Rico
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.